115 related articles for article (PubMed ID: 32550985)
1. PROTAC Compounds Targeting TRK for Use in Cancer Therapeutics.
Kargbo RB
ACS Med Chem Lett; 2020 Jun; 11(6):1090-1091. PubMed ID: 32550985
[No Abstract] [Full Text] [Related]
2. Specific MHC-I Peptides Are Induced Using PROTACs.
Jensen SM; Potts GK; Ready DB; Patterson MJ
Front Immunol; 2018; 9():2697. PubMed ID: 30524438
[TBL] [Abstract][Full Text] [Related]
3. PROTAC Compounds Targeting Androgen Receptor for Cancer Therapeutics: Prostate Cancer and Kennedy's Disease.
Kargbo RB
ACS Med Chem Lett; 2020 Jun; 11(6):1092-1093. PubMed ID: 32550986
[No Abstract] [Full Text] [Related]
4. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting TRK Proteins in Clinical Cancer Therapy.
Lange AM; Lo HW
Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29617282
[TBL] [Abstract][Full Text] [Related]
6. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
Lai AC; Toure M; Hellerschmied D; Salami J; Jaime-Figueroa S; Ko E; Hines J; Crews CM
Angew Chem Int Ed Engl; 2016 Jan; 55(2):807-10. PubMed ID: 26593377
[TBL] [Abstract][Full Text] [Related]
7. PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy.
Qi SM; Dong J; Xu ZY; Cheng XD; Zhang WD; Qin JJ
Front Pharmacol; 2021; 12():692574. PubMed ID: 34025443
[TBL] [Abstract][Full Text] [Related]
8. Degradation of proteins by PROTACs and other strategies.
Wang Y; Jiang X; Feng F; Liu W; Sun H
Acta Pharm Sin B; 2020 Feb; 10(2):207-238. PubMed ID: 32082969
[TBL] [Abstract][Full Text] [Related]
9. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
Zeng S; Huang W; Zheng X; Liyan Cheng ; Zhang Z; Wang J; Shen Z
Eur J Med Chem; 2021 Jan; 210():112981. PubMed ID: 33160761
[TBL] [Abstract][Full Text] [Related]
10. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
[TBL] [Abstract][Full Text] [Related]
11. Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1.
Hu M; Zhou W; Wang Y; Yao D; Ye T; Yao Y; Chen B; Liu G; Yang X; Wang W; Xie Y
Acta Pharm Sin B; 2020 Oct; 10(10):1943-1953. PubMed ID: 33163345
[TBL] [Abstract][Full Text] [Related]
12. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
13. Targeting BET Proteins With a PROTAC Molecule Elicits Potent Anticancer Activity in HCC Cells.
Zhang H; Li G; Zhang Y; Shi J; Yan B; Tang H; Chen S; Zhang J; Wen P; Wang Z; Pang C; Li J; Guo W; Zhang S
Front Oncol; 2019; 9():1471. PubMed ID: 31993368
[No Abstract] [Full Text] [Related]
14. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
[TBL] [Abstract][Full Text] [Related]
15. Monitoring and deciphering protein degradation pathways inside cells.
Daniels DL; Riching KM; Urh M
Drug Discov Today Technol; 2019 Apr; 31():61-68. PubMed ID: 31200861
[TBL] [Abstract][Full Text] [Related]
16. Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
Yang J; Li Y; Aguilar A; Liu Z; Yang CY; Wang S
J Med Chem; 2019 Nov; 62(21):9471-9487. PubMed ID: 31560543
[TBL] [Abstract][Full Text] [Related]
17. The PROTAC technology in drug development.
Zou Y; Ma D; Wang Y
Cell Biochem Funct; 2019 Jan; 37(1):21-30. PubMed ID: 30604499
[TBL] [Abstract][Full Text] [Related]
18. Trk kinase inhibitors as new treatments for cancer and pain.
Wang T; Yu D; Lamb ML
Expert Opin Ther Pat; 2009 Mar; 19(3):305-19. PubMed ID: 19441906
[TBL] [Abstract][Full Text] [Related]
19. Targeting Nuclear Receptors with PROTAC degraders.
Flanagan JJ; Neklesa TK
Mol Cell Endocrinol; 2019 Aug; 493():110452. PubMed ID: 31125586
[TBL] [Abstract][Full Text] [Related]
20. Small molecule Trk receptor agonists and other neurotrophic factor mimetics.
Pollack SJ; Harper SJ
Curr Drug Targets CNS Neurol Disord; 2002 Feb; 1(1):59-80. PubMed ID: 12769635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]